ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    SMT C1100
Previous Study | Return to List | Next Study

Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02383511
Recruitment Status : Completed
First Posted : March 9, 2015
Last Update Posted : August 26, 2015
Sponsor:
Information provided by (Responsible Party):
Summit Therapeutics

Brief Summary:
Placebo-controlled, multi-centre, randomized, double-blind dose escalation study. The aim is to evaluate the pharmacokinetics (PK) and safety of SMT C1100 in paediatric patients with Duchenne Muscular Dystrophy (DMD) who follow a balanced diet.

Condition or disease Intervention/treatment Phase
Muscular Dystrophy, Duchenne Drug: SMT C1100 Phase 1

Detailed Description:

Primary Objective:

To determine the plasma concentration of SMT C1100 calculated at each time point for each subject (sample size (n), mean, standard deviation (SD), percentage of coefficient of variation (%CV), geometric mean, median, minimum, and maximum for the parent and the major metabolites).

Secondary Objectives:

  1. To determine the safety and tolerability of single and multiple oral doses of SMT C1100 in patients with Duchenne Muscular Dystrophy (DMD) by assessing the participants adverse events, ECG results, vital signs and laboratory tests.
  2. To evaluate the diurnal variability in the steady state PK of SMT C1100 calculated at each time point for each subject (sample size (n), mean, standard deviation (SD), percentage of coefficient of variation (%CV), geometric mean, median, minimum, and maximum for the parent and the major metabolites).
  3. To evaluate reductions in creatine phosphokinase as a potential pharmacodynamic (PD) marker of SMT C1100 activity and clinical benefit.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1b Placebo-controlled, Multi-centre, Randomized, Double-blind Dose Escalation Study to Evaluate the Pharmacokinetics (PK) and Safety of SMT C1100 in Patients With Duchenne Muscular Dystrophy (DMD) Who Follow a Balanced Diet
Study Start Date : February 2015
Actual Primary Completion Date : August 2015
Actual Study Completion Date : August 2015


Arm Intervention/treatment
Sequence 1
Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
Drug: SMT C1100
Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID

Sequence 2
Drug: SMT C1100 or placebo 3-treatment (Period 1,2, and 3)
Drug: SMT C1100
Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID

Sequence 3
Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
Drug: SMT C1100
Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID




Primary Outcome Measures :
  1. Pharmacokinetic parameters at different dose levels of SMT C1100 [ Time Frame: 28 days ]
    To determine the plasma concentration of SMT C1100 parent and the major metabolites calculated at each time point for each subject.


Secondary Outcome Measures :
  1. Safety and tolerability of SMT C1100 [ Time Frame: 28 days ]
    To determine the safety and tolerability of single and multiple oral doses of SMT C1100 in patients with Duchenne Muscular Dystrophy (DMD) by assessing the participants adverse events.

  2. Evaluation of plasma CK levels [ Time Frame: 42 days ]
    To evaluate reductions in plasma creatine phosphokinase as a potential pharmacodynamic (PD) marker of SMT C1100 activity and muscle benefit.

  3. Pharmacokinetic parameters at different dose levels of SMT C1100 [ Time Frame: 28 Days ]
    To determine the plasma concentration of SMT C1100 major metabolites calculated at each time point for each subject.

  4. Safety and tolerability of SMT C1100 [ Time Frame: 28 Days ]
    To determine the safety and tolerability of single and multiple oral doses of SMT C1100 in patients with Duchenne Muscular Dystrophy (DMD) composite assessment of the participant's ECG results and laboratory tests.

  5. Pharmacokinetic parameters at different dose levels of SMT C1100 [ Time Frame: 28 Days ]
    To evaluate the diurnal variability in the steady state PK of SMT C1100 calculated at each time point for each subject.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years to 13 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients will be males of any ethnic origin with a genetic diagnosis of DMD.
  2. Children between 5 and 13 years of age.
  3. A parent/legal guardian must date and sign a written consent on behalf of the patient, according to International Conference on Harmonisation (ICH) and local regulations. This person must understand the contents of the consent, requirements of the study and have had an opportunity to review questions with a medically trained member of the site study team.
  4. The patient is willing to give verbal or written age appropriate assent to participate.
  5. For safety reasons, the patient's parent/legal guardian must have a good understanding of the English language, which the consent/assent forms are available, and understand the requirements for reporting of any AE to the Investigator.
  6. The patient has 6 months or more stable systemic (Patients using an intermittent regimen of steroid are allowed to be enrolled) corticosteroid therapy prior to Screening. Dose modifications for body weight are permitted.
  7. The patient or parent is willing to adhere to a balanced diet from 1 week prior to dosing until the end of the follow-up period.
  8. Patients must agree to not have sexual intercourse during the study treatment phases and until the end of their participation in the study.

Exclusion Criteria:

  1. Enrolment or participation in any therapeutic clinical trial within the prior 3 months or 5 times the half-life (whichever is longer). Prior exposure to SMT C1100 is NOT an exclusion criterion.
  2. Known hypersensitivity to the excipients of the study drug or a previous history of drug allergy.
  3. The patient or parent is unwilling to adhere to a balanced diet from 1 week prior to dosing until the end of the follow-up period.
  4. Is dairy or lactose intolerant, has an allergy to egg or nuts or any other dietary restrictions that might interfere with the conduct of the study.
  5. Is unable to refrain from eating cruciferous vegetables and barbecued (chargrilled) meat for the duration of the study.
  6. Use of prohibited medication within 5 half-lives prior to baseline assessments, unless otherwise stated in protocol.
  7. Need for mechanical ventilation.
  8. The patient experiences intermittent or continuous difficulties in swallowing.
  9. Non ambulatory.
  10. Any clinically significant acute illness within 4 weeks of the start of dose administration.
  11. Any comorbidity that, in the opinion of the Investigator, increases the risk of participating in the study.
  12. Symptomatic cardiomyopathy that in the opinion of the Investigator prohibits participation in this study.
  13. Abnormality in the 12-lead ECG at the Screening visit that, in the opinion of the Investigator, increases the risk of participating in the study.
  14. Any clinically significant medical condition, other than DMD that in the opinion of the Investigator may increase the risk of participating in the study or interfere with the interpretation of safety or efficacy evaluations (e.g., concomitant illness, severe reflux, psychiatric condition or behavioural disorder).
  15. The Patient smokes or has exposure to daily passive smoking (including parent/legal guardian, siblings) so as to minimise environmental factors causing CYP 1A induction.
  16. Excessive exercise (Investigator opinion).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02383511


Locations
United Kingdom
Heart of England NHS Foundation Trust - Heart Lands Hospital
Birmingham, United Kingdom, B9 5SS
Alder Hey Children's NHS Foundation Trust
Liverpool, United Kingdom, L12 2AP
Great Ormond Street Hospital for Children NHS Foundation Trust
London, United Kingdom, WC1N 3JH
Central Manchester University Hospitals NHS Foundation Trust- Royal Manchester Children's Hospital
Manchester, United Kingdom
Sponsors and Collaborators
Summit Therapeutics

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Summit Therapeutics
ClinicalTrials.gov Identifier: NCT02383511     History of Changes
Other Study ID Numbers: SMT C11003
First Posted: March 9, 2015    Key Record Dates
Last Update Posted: August 26, 2015
Last Verified: August 2015

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked